Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on cli...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Wawruszak, Anna, Kalafut, Joanna, Okon, Estera, Czapinski, Jakub, Halasa, Marta, Przybyszewska, Alicja, Miziak, Paulina, Okla, Karolina, Rivero-Muller, Adolfo, Stepulak, Andrzej
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406474/
https://ncbi.nlm.nih.gov/pubmed/30691229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020148
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky